Last reviewed · How we verify
A Phase IV, Uncontrolled, Open-label, Single-center Study in Adolescents and Adults: Evaluation of Immunogenicity and Safety of the First Booster Immunization With Novartis' TBE Vaccine for Adults in Participants of Study V48P7 and Long-term Evaluation of Immunogenicity up to 5 Years After First Booster Immunization
evaluate safety and immunogenicity of first TBE booster and long-term immunogenicity up to 5 years after first TBE booster
Details
| Lead sponsor | Novartis Vaccines |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 323 |
| Start date | 2006-09 |
| Completion | 2011-10 |
Conditions
- Tick Born Encephalitis
Interventions
- TBE vaccine for adults
Primary outcomes
- immunogenicity of TBE vaccine for adults when given as first booster dose as measured by neutralisation test and ELISA — On day 21, year 1, year 2, year 3, year 4, year 5
Countries
Czechia